Across TCGA pan-cancer cohorts, NAT8B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated NAT8B data layer compared with 26 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NAT8B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NAT8B expression acts as an unfavorable survival marker.

LUAD and GBM are the cancer types where NAT8B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.079	0.812	<.001	24	view →
GBM	OS	Median	All	0.030	0.416	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: NAT8B tumor-vs-normal RNA expression · all NAT8B data types